ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Jacksonville, FL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Jacksonville, FL, USA:

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Jacksonville, Florida, United States and 166 other locations

CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small...

Active, not recruiting
Relapsed Cancer
TNBC - Triple-Negative Breast Cancer
Biological: LYL797

Phase 1

Lyell Immunopharma

Jacksonville, Florida, United States and 17 other locations

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Jacksonville, Florida, United States and 288 other locations

cancers.* Part D will find out if and how much SGN-B7H4V can be given with pembrolizumab.* Part E will use the amount found in Part D to fi ...

Enrolling
Ovarian Neoplasms
Hormone Receptor Positive Breast Neoplasms
Drug: SGN-B7H4V
Drug: Pembrolizumab

Phase 1

Seagen
Seagen

Jacksonville, Florida, United States and 18 other locations

including metastatic colorectal cancer (mCRC) patients....

Enrolling
Cancer
Drug: cetuximab
Drug: FOLFIRI

Phase 1

Tizona Therapeutics

Fleming Island, Florida, United States and 38 other locations

The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standa...

Enrolling
Triple Negative Breast Cancer (TNBC)
Esophageal Cancer
Drug: Zimberelimab
Drug: Leucovorin

Phase 1

Arcus Biosciences
Arcus Biosciences

Jacksonville, Florida, United States and 13 other locations

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors...

Active, not recruiting
Non Small Cell Lung Cancer
Head and Neck Cancer
Biological: PD-1 inhibitor
Biological: CAB-ROR2-ADC

Phase 1, Phase 2

BioAtla

Fleming Island, Florida, United States and 58 other locations

with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of ...

Active, not recruiting
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Biological: Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Biological: Acasunlimab

Phase 1, Phase 2

Genmab
Genmab

Jacksonville, Florida, United States and 56 other locations

-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), end...

Active, not recruiting
Castration-resistant Prostate Cancer
Lower Esophageal Cancer
Drug: cabozantinib
Drug: atezolizumab

Phase 1, Phase 2

Exelixis
Exelixis

Jacksonville, Florida, United States and 123 other locations

systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided...

Enrolling
Stage IIB Breast Cancer AJCC V6 and V7
Stage II Breast Cancer AJCC V6 and V7
Radiation: Whole Breast Irradiation
Other: Laboratory Biomarker Analysis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center

Jacksonville, Florida, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems